Currently out of the existing stock ratings of Sumant Kulkarni, 149 are a BUY (86.63%), 23 are a HOLD (13.37%).

Sumant Kulkarni

Work Performance Price Targets & Ratings Chart

Analyst Sumant Kulkarni, currently employed at CANACCORD, carries an average stock price target met ratio of 40.33% that have a potential upside of 33.58% achieved within 175 days.

Sumant Kulkarni’s has documented 340 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GHRS, GH Research PLC at 06-Jan-2026.

Wall Street Analyst Sumant Kulkarni

Analyst best performing recommendations are on CARA (CARA THERAPEUTIC).
The best stock recommendation documented was for CARA (CARA THERAPEUTIC) at 6/13/2024. The price target of $10 was fulfilled within 4 days with a profit of $5.97 (37.38%) receiving and performance score of 93.46.

Average potential price target upside

of $207.41 (72.96%) on BTAI (BIOXCEL THERAPEUTICS).
of $54.47 (20.96%) on BIIB (BIOGEN).
of $45.85 (58.11%) on CARA (CARA THERAPEUTIC).

ACAD ACADIA Pharmaceuticals ATAI ATAI Life Sciences BV BHVN Biohaven Pharmaceutical Holding Co Ltd BIIB Biogen BTAI BioXcel Therapeutics CRTX Cortexyme ITCI Intracellular Th NBIX Neurocrine Biosciences SAGE Sage Therapeutic VYGR Voyager Therapeutics ZYNE Zynerba Pharmaceuticals CARA Cara Therapeutic CMPS Compass Pathways Plc CYBN Cybin KMPH KemPharm TEVA Teva Pharma Industries Ltd ADR ALDR Alder BioPharmaceuticals CLNN Clene ANVS Annovis Bio GHRS GH Research PLC MNMD Mind Medicine STOK Stoke Therapeutics CRVO CervoMed AKRX Akorn

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score